FP7H2020
Alta Ricerca e Sviluppo in Biotecnologie Srlu
- Country
- ITItaly
- Defence projects
- 0
- Projects, all programmes
- 25
- As coordinator
- 0
- EU contribution (CORDIS)
- EUR 4,070,674
- Active
- 2008 to 2019
Projects
25 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| ENDONANOQuantitative detection of bacterial endotoxin by novel nanotechnological approaches | H2020 | 2019 | Partner | EUR 0 |
| HIPGENPlacenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicenter phase III trial | H2020 | 2018 | Participant | EUR 190,000 |
| PACEA multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies | H2020 | 2017 | Participant | EUR 224,000 |
| LIVERHOPESIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS | H2020 | 2017 | Participant | EUR 153,101 |
| HEP-CARMechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities. | H2020 | 2016 | Participant | EUR 180,000 |
| MarPipeImproving the flow in the pipeline of the next generation of marine biodiscovery scientists | H2020 | 2016 | Partner | EUR 0 |
| PANDORAProbing safety of nano-objects by defining immune responses of environmental organisms | H2020 | 2016 | Partner | EUR 0 |
| ImmunoAgeingAn integrated approach to dissect determinants, risk factors and pathways of ageing of the immune system. | H2020 | 2015 | Participant | EUR 200,000 |
| GLYCOVAXA training network for the rational design of the next generation of well-defined glycoconjugate vaccines | H2020 | 2015 | Partner | EUR 0 |
| BioCogBiomarker Development for Postoperative Cognitive Impairment in the Elderly | FP7 | 2014 | Participant | EUR 150,000 |
| Athero-FluxTargeting novel lipid pathways for treatment of cardiovascular disease | FP7 | 2013 | Participant | EUR 170,000 |
| Athero-B-CellTargeting and exploiting B cell functions for treatment in cardiovascular disease | FP7 | 2013 | Participant | EUR 170,000 |
| HERACLESHuman cystic Echinococcosis ReseArch in CentraL and Eastern Societies | FP7 | 2013 | Participant | EUR 125,000 |
| ABIRISKAnti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk | FP7 | 2012 | Participant | EUR 438,672 |
| PathCOPathogen COinfection: HIV, Tuberculosis, Malaria and Hepatitis C virus | FP7 | 2012 | Participant | EUR 144,000 |
| TIMERTargetIng novel MEchanisms of Resolution in inflammation | FP7 | 2012 | Participant | EUR 100,000 |
| TARKINAIDTargeting Src-family tyrosine kinases in chronic autoimmune and inflammatory diseases | FP7 | 2012 | Participant | EUR 100,000 |
| BIO-DrIMPersonalized minimization of immunosuppression after solid organ transplantation by biomarker-driven stratification of patients to improve long-term outcome and health-economic data of transplantation | FP7 | 2012 | Participant | EUR 229,600 |
| ADITECAdvanced Immunization Technologies | FP7 | 2011 | Participant | EUR 265,000 |
| PANACREASIntegrating chemical approaches to treat pancreatic cancer: making new leads for a cure | FP7 | 2011 | Participant | EUR 89,601 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.